Home/Filings/4/0001055726-25-000003
4//SEC Filing

Shea Jacqueline Elizabeth 4

Accession 0001055726-25-000003

CIK 0001055726other

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 6:05 PM ET

Size

19.4 KB

Accession

0001055726-25-000003

Insider Transaction Report

Form 4
Period: 2025-02-26
Shea Jacqueline Elizabeth
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-26+5,85239,499 total
  • Tax Payment

    Common Stock

    2025-02-26$1.98/sh2,493$4,93637,006 total
  • Exercise/Conversion

    Common Stock

    2025-02-26+18,63255,638 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-265,8520 total
    Common Stock (5,852 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-2618,63237,263 total
    Common Stock (18,632 underlying)
  • Award

    Common Stock Option

    2025-02-27+105,649105,649 total
    Exercise: $1.94From: 2025-02-27Exp: 2035-02-27Common Stock (105,649 underlying)
  • Award

    Restricted Stock Unit

    2025-02-27+85,20185,201 total
    Common Stock (85,201 underlying)
  • Tax Payment

    Common Stock

    2025-02-26$1.98/sh9,088$17,99446,550 total
Footnotes (6)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units granted on February 26, 2022 was as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
  • [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 is as follows: 18,632 shares vested on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
  • [F4]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein.
  • [F5]The vesting schedule for the 105,649 options is as follows: 52,825 shares vested on February 27, 2025 and 52,824 shares will vest on February 26, 2026.
  • [F6]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 is as follows: 28,401 shares will vest on February 26, 2026; 28,400 shares will vest on February 26, 2027; and 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Issuer

INOVIO PHARMACEUTICALS, INC.

CIK 0001055726

Entity typeother

Related Parties

1
  • filerCIK 0001771498

Filing Metadata

Form type
4
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 6:05 PM ET
Size
19.4 KB